Asunto(s)
COVID-19 , Canalopatías , Canales Iónicos/metabolismo , Síndrome de QT Prolongado , Células Musculares , SARS-CoV-2 , COVID-19/complicaciones , COVID-19/metabolismo , COVID-19/fisiopatología , Canalopatías/metabolismo , Canalopatías/fisiopatología , Canalopatías/prevención & control , Canalopatías/virología , Sistema de Conducción Cardíaco/metabolismo , Sistema de Conducción Cardíaco/virología , Interacciones Microbiota-Huesped , Factores Celulares Derivados del Huésped/metabolismo , Humanos , Síndrome de QT Prolongado/etiología , Síndrome de QT Prolongado/metabolismo , Síndrome de QT Prolongado/prevención & control , Síndrome de QT Prolongado/virología , Células Musculares/fisiología , Células Musculares/virología , SARS-CoV-2/patogenicidad , SARS-CoV-2/fisiologíaRESUMEN
Ion channels play key roles in almost all facets of cellular physiology and have emerged as key host cell factors for a multitude of viral infections. A catalogue of ion channel-blocking drugs have been shown to possess antiviral activity, some of which are in widespread human usage for ion channel-related diseases, highlighting new potential for drug repurposing. The emergence of ion channel-virus interactions has also revealed the intriguing possibility that channelopathies may explain some commonly observed virus induced pathologies. This field is rapidly evolving and an up-to-date summary of new discoveries can inform future perspectives. We herein discuss the role of ion channels during viral lifecycles, describe the recently identified ion channel drugs that can inhibit viral infections, and highlight the potential contribution of ion channels to virus-mediated disease.